Artificial intelligence (AI) neuroimaging technology firm Qynapse is collaborating with researchers at the University of Miami to explore the effects of COVID-19 on vascular contributions to cognitive impairment and dementia.
The University of Miami is recruiting 250 patients who will undergo deep phenotyping through the acquisition of clinical, neuropsychological, MRI, and biological data with a 24-month follow-up visit. Qynapse's QyScore software provides automatic segmentation and quantification of regional brain and white-matter hyperintensity volumes, and it will be deployed in this study to generate rapid, precise, and objective MRI brain imaging analysis, the company said.
Neurological symptoms have been observed to different extents in patients with COVID-19, including strokes, headaches, seizures, anosmia, and dysgeusia, yet the association between the disease and cognitive impairment is poorly understood, Qynapse added.
